Real-world efficacy and problems of once-daily use of inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) in Japanese patients with asthma

References

• Adachi, M., Goldfrad, C., Jacques, L., & Nishimura, Y. (2016, Nov). Efficacy and safety comparison: Fluticasone furoate and fluticasone propionate, after step down from fluticasone furoate/vilanterol in Japanese patients with well-controlled asthma, a randomized trial. Respiratory Medicine, 120, 78–11. Epub 2016 Sep 30. doi:10.1016/j.rmed.2016.09.018.
   PubMed Web of Science ®Google Scholar
• Allen, A., Bareille, P. J., & Rousell, V. M. (2013). Fluticasone furoate, a novel inhaled corticosteroid, demonstrates prolonged lung absorption kinetics in man compared with inhaled fluticasone propionate. Clinical Pharmacokinetics, 52, 37–42.
   PubMed Web of Science ®Google Scholar
• Azevedo, K. S., Luiz, R. R., Rocco, P. R., & Conde, M. B. (2012). Vital capacity and inspiratory capacity as additional parameters to evaluate bronchodilator response in asthmatic patients: A cross sectional study. BMC Pulmonary Medicine, 12, 49.
   PubMed Web of Science ®Google Scholar
• Bateman, E. D., Bleecker, E. R., Lötvall, J., Woodcock, A., Forth, R., Medley, H., … Busse, W. W. (2012, May). Dose effect of once-daily fluticasone furoate in persistent asthma: A randomized trial. Respiratory Medicine, 106(5), 642–650. Epub 2012 Feb 18. doi: 10.1016/j.rmed.2012.01.004
   PubMed Web of Science ®Google Scholar
• Bernstein, D., Andersen, L., Forth, R., Jacques, L., & Yates, L. (2018, Sep). Once-daily fluticasone furoate/vilanterol versus twice-daily fluticasone propionate/salmeterol in patients with asthma well controlled on ICS/LABA. The Journal of Asthma, 55(9), 984–993. Epub 2018 Apr 13. doi: 10.1080/02770903.2017.1386214
   PubMed Web of Science ®Google Scholar
• Bernstein, D. I., Bateman, E. D., Woodcock, A., Toler, W. T., Forth, R., Jacques, L., … O’Byrne, P. M. (2015). Fluticasone furoate (FF)/vilanterol (100/25 mcg or 200/25 mcg) or FF (100 mcg) in persistent asthma. The Journal of Asthma, 52, 1073–1083.
   PubMed Web of Science ®Google Scholar
• Bleecker, E. R., Bateman, E. D., Busse, W. W., Woodcock, A., Frith, L., House, K. W., … Lötvall, J. (2012, Nov). Once-daily fluticasone furoate is efficacious in patients with symptomatic asthma on low-dose inhaled corticosteroids. Annals of Allergy, Asthma & Immunology, 109(5), 353–358.e4. doi:10.1016/j.anai.2012.08.017
   PubMed Web of Science ®Google Scholar
• Coleman, C. I., Limone, B., Sobieraj, D. M., Lee, S., Roberts, M. S., Kaur, R., & Alam, T. (2012, Sep). Dosing frequency and medication adherence in chronic disease. Journal of Managed Care Pharmacy : JMCP, 18(7), 527–539.
   PubMed Web of Science ®Google Scholar
• Daley-Yates, P. T. (2015). Inhaled corticosteroids: Potency, dose equivalence and therapeutic index. British Journal of Clinical Pharmacology, 80, 372–380.
   PubMed Web of Science ®Google Scholar
• Des Jardins, T., & Burton, G. G. (1995). Patient Assessment. In Clinical manifestations & assessment of respiratory disease (3rd ed., pp. 3–118). St. Louis: Mosby-Year Book, Inc.
   Google Scholar
• Devillier, P., Humbert, M., Boye, A., Zachgo, W., Jacques, L., Nunn, C., … Grouin, J. M. (2018). Efficacy and safety of once-daily fluticasone furoate/vilanterol (FF/VI) versus twice-daily inhaled corticosteroids/long-acting β2-agonists (ICS/LABA) in patients with uncontrolled asthma: An open-label, randomized, controlled trial. Respiratory Medicine, 141, 111–120.
   PubMed Web of Science ®Google Scholar
• Empey, D. W. (1972, Aug 26). Assessment of upper airways obstruction. British Medical Journal, 3(5825), 503–505.
   PubMed Web of Science ®Google Scholar
• Ernst, P., Spitzer, W. O., Suissa, S., Cockcroft, D., Habbick, B., Horwitz, R. I., … Buist, A. S. (1992, Dec 23–30). Risk of fatal and near-fatal asthma in relation to inhaled corticosteroid use. JAMA, 268(24), 3462–3464.
   PubMed Web of Science ®Google Scholar
• Global Initiative for Asthma (GINA). (2018). Global strategy for asthma management and prevention. Retrieved from https://ginasthma.org/wp-content/uploads/2018/04/wms-GINA-2018-report-V1.3-002.pdf
   Google Scholar
• Hayes, D., Jr, & Kraman, S. S. (2009). The physiologic basis of spirometry. Respiratory Care, 54, 1717–1726.
   PubMed Web of Science ®Google Scholar
• Hulley, S. B., Cummings, S. R., Browner, W. S., Grady, D. G., & Newman, T. B. (2013). Designing clinical research (4th ed.). Philadelphia, USA: Lippincott Williams & Wilkins, a Wolters Kluwer business.
   Google Scholar
• Kerwin, E., Barnes, N., Gibbs, M., Leather, D., Forth, R., Jacques, L., & Yates, L. J. (2018). Fluticasone furoate/vilanterol once daily improves night-time awakenings in asthma patients with night symptoms: Post hoc analyses of three randomized controlled trials. The Journal of Asthma, 55, 890–897.
   PubMed Web of Science ®Google Scholar
• Lin, J., Kang, J., Lee, S. H., Wang, C., Zhou, X., Crawford, J., … Stone, S. (2015). Fluticasone furoate/vilanterol 200/25 mcg in Asian asthma patients: A randomized trial. Respiratory Medicine, 109, 44–53.
   PubMed Web of Science ®Google Scholar
• Martinez, F. J., Vestbo, J., Anderson, J. A., Brook, R. D., Celli, B. R., Cowans, N. J., … Calverley, P. M. (2017). Effect of fluticasone furoate and vilanterol on exacerbations of chronic obstructive pulmonary disease in patients with moderate airflow obstruction. American Journal of Respiratory and Critical Care Medicine, 195, 881–888.
   PubMed Web of Science ®Google Scholar
• Mink, S. N., Greville, H., Gomez, A., & Eng, J. (1988, Jan). Expiratory flow limitation in dogs with regional changes in lung mechanical properties. Journal of Applied Physiology (1985), 64(1), 162–173.
   PubMed Web of Science ®Google Scholar
• Nathan, R. A., Sorkness, C. A., Kosinski, M., Schatz, M., Li, J. T., Marcus, P., … Pendergraft, T. B. (2004, Jan). Development of the asthma control test: A survey for assessing asthma control. The Journal of Allergy and Clinical Immunology, 113(1), 59–65.
   PubMed Web of Science ®Google Scholar
• Nomura, K., Asai, S., Muraoka, F., Kinjo, Y., Kadota, T., Oye, T., … Yamasaki, T. (1978). The relationship between airway lesions and pulmonary function in bronchial asthma. Nihon Kyobu Shikkan Gakkai Zasshi, 16, 173–179.
   PubMedGoogle Scholar
• O’Byrne, P. M., Bleecker, E. R., Bateman, E. D., Busse, W. W., Woodcock, A., Forth, R., … Lötvall, J. (2014). Once-daily fluticasone furoate alone or combined with vilanterol in persistent asthma. The European Respiratory Journal, 43, 773–782. doi:10.1183/09031936.00064513
   PubMed Web of Science ®Google Scholar
• Price, D., Robertson, A., Bullen, K., Rand, C., Horne, R., & Staudinger, H. (2010, Jan 5). Improved adherence with once-daily versus twice-daily dosing of mometasone furoate administered via a dry powder inhaler: A randomized open-label study. BMC Pulmonary Medicine, 10, 1. doi:10.1186/1471-2466-10-1
   PubMed Web of Science ®Google Scholar
• Rossios, C., To, Y., To, M., Ito, M., Barnes, P. J., Adcock, I. M., … Ito, K. (2011). Long-acting fluticasone furoate has a superior pharmacological profile to fluticasone propionate in human respiratory cells. European Journal of Pharmacology, 670, 244–251.
   PubMed Web of Science ®Google Scholar
• Salter, M., Biggadike, K., Matthews, J. L., West, M. R., Haase, M. V., Farrow, S. N., … Gray, D. W. (2007). Pharmacological properties of the enhanced-affinity glucocorticoid fluticasone furoate in vitro and in an in vivo model of respiratory inflammatory disease. American Journal of Physiology. Lung Cellular and Molecular Physiology, 293, L660–L667. doi:10.1152/ajplung.00108.2007
   PubMed Web of Science ®Google Scholar
• Siler, T. M., Nagai, A., Scott-Wilson, C. A., Midwinter, D. A., & Crim, C. (2017). A randomised, phase III trial of once-daily fluticasone furoate/vilanterol 100/25 μg versus once-daily vilanterol 25 μg to evaluate the contribution on lung function of fluticasone furoate in the combination in patients with COPD. Respiratory Medicine, 123, 8–17.
   PubMed Web of Science ®Google Scholar
• Szidon, J. P., & Fishman, A. P. (1988). Approach to the pulmonary patient with respiratory signs and symptoms. In A. P. Fishman (Ed.), Pulmonary diseases and disorders (2nd ed., pp. 313–366). New York: McGraw-Hill Book Company.
   Google Scholar
• Vestbo, J., Anderson, J. A., Brook, R. D., Calverley, P. M., Celli, B. R., Crim, C., … Newby, D. E. (2016). Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary disease with heightened cardiovascular risk (SUMMIT): A double-blind randomised controlled trial. Lancet, 387(10030), 1817–1826.
   PubMed Web of Science ®Google Scholar
• Vestbo, J., Leather, D., Diar Bakerly, N., New, J., Gibson, J. M., McCorkindale, S., … Woodcock, A. (2016). Effectiveness of fluticasone furoate-vilanterol for COPD in clinical practice. The New England Journal of Medicine, 375, 1253–1260.
   PubMed Web of Science ®Google Scholar
• Woodcock, A., Bleecker, E. R., Lötvall, J., O’Byrne, P. M., Bateman, E. D., Medley, H., … Busse, W. W. (2013, Oct). Efficacy and safety of fluticasone furoate/vilanterol compared with fluticasone propionate/salmeterol combination in adult and adolescent patients with persistent asthma: A randomized trial. Chest, 144(4), 1222–1229. doi:10.1378/chest.13-0178
   PubMed Web of Science ®Google Scholar
• Woodcock, A., Vestbo, J., Bakerly, N. D., New, J., Gibson, J. M., McCorkindale, S., … Leather, D. (2017). Salford lung study investigators. Effectiveness of fluticasone furoate plus vilanterol on asthma control in clinical practice: An open-label, parallel group, randomised controlled trial. Lancet, 390(10109), 2247–2255.
   PubMed Web of Science ®Google Scholar
• World Health Organization. (2019). Asthma: Definition. Retrieved from https://www.who.int/respiratory/asthma/definition/en/
   Google Scholar
• World Health Organization. (2019). Asthma. Retrieved from https://www.who.int/respiratory/asthma/en/
   Google Scholar